Luo Wanxian, Wen Ge, Yang Li, Tang Jiao, Wang Jianguo, Wang Jihui, Zhang Shiyu, Zhang Li, Ma Fei, Xiao Liling, Wang Ying, Li Yingjia
Department of Medicine Ultrasonics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China;; Guangdong Provincial Key laboratory of cancer immunotherapy research, Cancer Research Institute, School of Basic Medical Science, Southern Medical University, Guangzhou 510515, China.
Imaging center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Theranostics. 2017 Jan 5;7(2):452-465. doi: 10.7150/thno.16677. eCollection 2017.
In this study, we investigated the potential of a dual-targeted pH-sensitive doxorubicin prodrug-microbubble complex (DPMC) in ultrasound (US)-assisted antitumor therapy. The doxorubicin prodrug (DP) consists of a succinylated-heparin carrier conjugated with doxorubicin (DOX) hydrazone linkage and decorated with dual targeting ligands, folate and cRGD peptide. Combination of microbubble (MB) and DP, generated avidin-biotin binding, promoted intracellular accumulation and improved therapeutic efficiency assisted by US cavitation and sonoporation. Aggregates of prepared DP were observed with an inhomogeneous size distribution (average diameters: 149.6±29.8 nm and 1036.2±38.8 nm, PDI: 1.0) while DPMC exhibited a uniform distribution (average diameter: 5.804±2.1 μm), facilitating its usage for drug delivery. Notably, upon US exposure, DPMC was disrupted and aggregated DP dispersed into homogeneous small-sized nanoparticles (average diameter: 128.6±42.3 nm, PDI: 0.21). DPMC could target to angiogenic endothelial cells in tumor region αβ-mediated recognition and subsequently facilitate its specific binding to tumor cells mediated recognition of folate receptor (FR) after US exposure. experiments showed higher tumor specificity and killing ability of DPMC with US than free DOX and DP for breast cancer MCF-7 cells. Furthermore, significant accumulation and specificity for tumor tissues of DPMC with US were detected using fluorescence and ultrasound molecular imaging, indicating its potential to integrate tumor imaging and therapy. In particular, through inducing apoptosis, inhibiting cell proliferation and antagonizing angiogenesis, DPMC with US produced higher tumor inhibition rates than DOX or DPMC without US in MCF-7 xenograft tumor-bearing mice while inducing no obvious body weight loss. Our strategy provides an effective platform for the delivery of large-sized or aggregated particles to tumor sites, thereby extending their therapeutic applications .
在本研究中,我们探究了双靶点pH敏感阿霉素前药-微泡复合物(DPMC)在超声辅助抗肿瘤治疗中的潜力。阿霉素前药(DP)由与阿霉素(DOX)通过腙键连接的琥珀酰化肝素载体组成,并装饰有双靶向配体叶酸和cRGD肽。微泡(MB)与DP结合,通过抗生物素蛋白-生物素结合产生,促进细胞内积累,并在超声空化和声孔效应的辅助下提高治疗效率。观察到制备的DP聚集体大小分布不均匀(平均直径:149.6±29.8 nm和1036.2±38.8 nm,PDI:1.0),而DPMC呈现均匀分布(平均直径:5.804±2.1μm),便于其用于药物递送。值得注意 的是,在超声照射下,DPMC被破坏,聚集的DP分散成均匀的小尺寸纳米颗粒(平均直径:128.6±42.3 nm,PDI:0.21)。DPMC可通过αβ介导的识别靶向肿瘤区域的血管生成内皮细胞,并随后在超声照射后促进其通过叶酸受体(FR)介导的识别与肿瘤细胞的特异性结合。实验表明,与游离DOX和DP相比,DPMC联合超声对乳腺癌MCF-7细胞具有更高的肿瘤特异性和杀伤能力。此外,使用荧光和超声分子成像检测到DPMC联合超声对肿瘤组织具有显著的积累和特异性,表明其具有整合肿瘤成像和治疗的潜力。特别是,通过诱导凋亡、抑制细胞增殖和拮抗血管生成,DPMC联合超声在MCF-7异种移植荷瘤小鼠中产生的肿瘤抑制率高于DOX或无超声的DPMC,同时未引起明显的体重减轻。我们的策略为将大尺寸或聚集颗粒递送至肿瘤部位提供了一个有效的平台,从而扩展了它们的治疗应用。